Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study

BACKGROUND: Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis despite the availability of multiple treatment options. Preliminary evidence suggests that DLBCL may be responsive to programmed death ligand 1 (PD-L1)/programmed death 1 inhibitors. OBJEC...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawkes, Eliza A., Phillips, Tycel, Budde, Lihua Elizabeth, Santoro, Armando, Saba, Nakhle S., Roncolato, Fernando, Gregory, Gareth P., Verhoef, Gregor, Offner, Fritz, Quero, Cristina, Radford, John, Giannopoulos, Krzysztof, Stevens, Don, Thall, Aron, Huang, Bo, Laird, A. Douglas, Sandner, Robin, Ansell, Stephen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613117/
https://www.ncbi.nlm.nih.gov/pubmed/34687398
http://dx.doi.org/10.1007/s11523-021-00849-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613117/
https://www.ncbi.nlm.nih.gov/pubmed/34687398
http://dx.doi.org/10.1007/s11523-021-00849-8

Ejemplares similares